Abstract
Introduction
Continuous glucose monitoring (CGM) introduces novel indicators of glycemic control.
Methods
This cross-sectional study, based on the Swedish National Diabetes Register, examines 27,980 adults with type 1 diabetes. It explores the relationships between HbA1c (glycated hemoglobin) and various CGM-derived metrics, including TIR (time in range, representing the percentage of time within the range of 4–10 mmol/l for 2 weeks), TAR (time above range), TBR (time below range), mean glucose, standard deviation (SD), and coefficient of variation (CV). Pearson correlation coefficients and linear regression models were utilized for estimation.
Results
The analysis included 46% women, 30% on insulin pump, 7% with previous coronary heart disease and 64% with retinopathy. Mean ± SD values were age 48 ± 18 years, diabetes duration 25 ± 16 years, HbA1c 58.8 ± 12.8 mmol/mol, TIR 58.8 ± 19.0%, TAR 36.3 ± 20.0%, TBR 4.7 ± 5.4%, mean sensor glucose 9.2 ± 2.0 mmol/l, SD 3.3 ± 1.0 mmol/l, and CV 36 ± 7%. The overall association between HbA1c and TIR was − 0.71 (Pearson’s r), with R2 0.51 in crude linear regression and 0.57 in an adjusted model. R2 values between HbA1c and CGM mean glucose were 0.605 (unadjusted) 0.619 (adjusted) and TAR (unadjusted 0.554 and fully adjusted 0.568, respectively), while fully adjusted R2 values were 0.458, 0.175 and 0.101 between HbA1c and CGM SD, CGM CV and TBR, respectively.
Conclusions
This descriptive study demonstrates that the degree of association between HbA1c and new and readily available CGM-derived metrics, i.e., time in range (TIR), time above range (TAR), and CGM mean glucose, is robust in assessing the management of individuals with type 1 diabetes in clinical settings. Metrics from CGM that pertain to variability and hypoglycemia exhibit only weak correlations with HbA1c.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Allansson Kjölhede, Elin 2 ; Salö, Sofia 3 ; Fabrin Nielsen, Nick 4 ; Eeg-Olofsson, Katarina 5 1 Sahlgrenska University Hospital, Department of Medicine, Göteborg, Sweden (GRID:grid.1649.a) (ISNI:0000 0000 9445 082X); Västra Götalandsregionen, Centre of Registers, Göteborg, Sweden (GRID:grid.452005.6) (ISNI:0000 0004 0405 8808)
2 Sahlgrenska University Hospital, Department of Medicine, Göteborg, Sweden (GRID:grid.1649.a) (ISNI:0000 0000 9445 082X); University of Gothenburg, Department of Molecular and Clinical Medicine, Institute of Medicine, Göteborg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
3 Novo Nordisk Scandinavia AB, Malmö, Sweden (GRID:grid.519389.f)
4 Novo Nordisk A/S, Søborg, Denmark (GRID:grid.425956.9) (ISNI:0000 0004 0391 2646)
5 Sahlgrenska University Hospital, Department of Medicine, Göteborg, Sweden (GRID:grid.1649.a) (ISNI:0000 0000 9445 082X); Västra Götalandsregionen, Centre of Registers, Göteborg, Sweden (GRID:grid.452005.6) (ISNI:0000 0004 0405 8808); University of Gothenburg, Department of Molecular and Clinical Medicine, Institute of Medicine, Göteborg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)





